STERIS plc STE reported fourth-quarter fiscal 2021 adjusted earnings per share (EPS) of $1.63, flat with the year-ago figure. However, the metric lagged the Zacks Consensus Estimate by 9.4%.
The adjustment excludes the impact of certain non-recurring charges like COVID-led incremental costs, amortization of acquired intangible assets, acquisition and integration-related charges, and amortization of property step up to fair value.
The company’s GAAP EPS was $1.02, down 28.7% year over year.
Full-year adjusted EPS was $6.17, reflecting a 9.4% increase from the year-earlier $5.64. The metric missed the Zacks Consensus Estimate by 2.3%.
Revenues in Detail
Revenues of $873.5 million improved 6.1% year over year in the quarter. Further, the metric exceeded the Zacks Consensus Estimate by 0.3%. The year-over-year uptick was led by robust sales in all of the company’s three reporting segments.
Organic revenues at constant currency or CER rose 0.3% year over year in the fiscal fourth quarter.
Full-year revenues totaled $3.11 billion, reflecting a 2.5% increase from the year-ago period. Revenues beat the Zacks Consensus Estimate by 0.3%.
Quarter in Detail
The company operates through three segments — Healthcare, Applied Sterilization Technologies and Life Sciences.
Revenues at Healthcare rose 2.8% year over year to $561.8 million (down 4.2% on a CER organic basis). This performance reflected a 25% increase in consumable revenues, driven by the addition of $32.1 million in revenues from Key Surgical. Meanwhile, service revenues and capital equipment revenues fell 4%.
Revenues at Applied Sterilization Technologies improved 14.6% to $187.5 million (up 10.1% at CER organic basis). CER organic revenues reflected increased demand from medical device customers during the quarter.
STERIS plc Price, Consensus and EPS Surprise
STERIS plc price-consensus-eps-surprise-chart | STERIS plc Quote
Revenues at the Life Sciences segment rose 10.2% to $124.2 million (up 7.5% at CER organic basis) on 43% growth in capital equipment revenues and 5% growth in service revenues. This was offset by a 4% decline in consumable revenues.
Gross profit in the reported quarter was $379.7 million, up 4.6% from the prior-year quarter’s adjusted gross profit (excluding costs and benefits of revenues for restructuring). Gross margin contracted 63 basis points (bps) year over year to 43.5% in the reported quarter.
STERIS witnessed a 16.9% year-over-year uptick in selling, general and administrative expenses to $221.1 million. Research and development expenses, however, rose 1.7% to $17.5 million. Adjusted operating expenses of $238.6 million, rose 15.7% year over year.
Adjusted operating profit totaled $141.1 million, reflecting a 9.9% fall from the prior-year quarter. Meanwhile, adjusted operating margin also contracted 287 bps to 16.2%.
STERIS exited 2021 with cash and cash equivalents of $220.5 million compared with $319.6 million at the end of 2020.
Cumulative net cash flow from operating activities at the end of 2021 was $689.6 million compared with $590.6 million a year ago.
The company’s free cash flow at the end of 2021 was $450.9 million compared with $380.2 million in the year-ago period. Capital expenditure of the company at the end of 2021 was $239.3 million, up from $214.5 million in the year-ago period.
The company approved a quarterly interim dividend of 40 cents per share to shareholders.
STERIS has provided financial guidance for fiscal 2022. The guidance includes business integration of the ongoing Cantel Medical buyout. The acquisition is expected to get completed on Jun 2.
The company expects reported revenues to be nearly $4.5 billion while constant currency organic revenue growth is projected in the range of 8-9% for fiscal 2022. The Zacks Consensus Estimate for the same is pegged at $3.74 billion.
Adjusted earnings per diluted share are anticipated in the band of $7.40-$7.65. The Zacks Consensus Estimate for the metric is pegged at $6.97.
STERIS exited fourth-quarter fiscal 2021 on a mixed noted with a revenue beat and earnings miss. The company witnessed solid revenue growth across three of its reporting segments amid the post-pandemic recovery. Contributions from the Key Surgical buyout, elevated consumer demand and rebound in procedure volumes along with strength in segments catering to COVID-related products and services are encouraging. An increase in free cash flow despite increased capital spending instills optimism. Further, the company has issued its fiscal 2022 guidance, projecting growth over 2020.
However, escalating operating costs and contraction in both margins during the quarter are concerning.
Zacks Rank and Key Picks
STERIS currently carries a Zacks Rank #3 (Hold).
A few better-ranked stocks in the broader medical space are National Vision Holdings, Inc. EYE, Illumina, Inc. ILMN and HCA Healthcare, Inc. HCA.
National Vision reported first-quarter 2021 adjusted EPS of 48 cents, beating the Zacks Consensus Estimate by 45.5%. Net revenues of $534.2 million outpaced the consensus estimate by 3.1%. It currently carries Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Illumina reported first-quarter 2021 adjusted EPS of $1.89, beating the Zacks Consensus Estimate by 38.9%. Revenues of $1.09 billion outpaced the consensus estimate of $1.08 billion. It currently carries Zacks Rank #2.
HCA Healthcare reported first-quarter 2021 adjusted EPS of $4.14, surpassing the Zacks Consensus Estimate by 23.6%. Net revenues of $14 billion exceeded the Zacks Consensus Estimate by 2.2%. It currently carries Zacks Rank #2.
5 Stocks Set to Double
Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Illumina, Inc. (ILMN) : Free Stock Analysis Report
HCA Healthcare, Inc. (HCA) : Free Stock Analysis Report
STERIS plc (STE) : Free Stock Analysis Report
National Vision Holdings, Inc. (EYE) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research